Eisai Realigns US Operations - Reduces its Workforce by 25%
![](/46/pdcnewsitem/03/43/72/tCAWnuylNh6rd0V.jpg)
Eisai Inc., a US subsidiary of Eisai Co., Ltd., has announced plans to realign its operations in the US. As part of this restructuring, Eisai Inc. will reduce its workforce by approximately 25% across various US functions. This realignment supports Eisai's desire to create a more efficient and focused organization.
"The actions we are taking will ensure Eisai stays competitive in a rapidly changing business environment," said Yuji Matsue, Chairman and CEO of Eisai Inc. "Eisai remains fully committed to the US market and will continue to serve the needs of patients and their families by developing and marketing important new treatments that help to satisfy unmet medical needs. Through this realignment, we will be able to redeploy our resources to support the development of our priority late-stage compounds and our current product portfolio."
The new structure is expected to be in place by 1 May 2015. Eisai's US operations include R&D, manufacturing, sales and marketing, and administrative functions. The company does not have plans to close any of its main offices or facilities.
"This decision was difficult," said Shaji Procida, President and COO of Eisai Inc. "We are grateful to our colleagues, each of whom has played an important role in helping us fulfil our human health care (hhc) mission of bringing important new medicines to patients. We are aware of the impact that our reorganization will have on some employees and will work with them to ensure that their transition is as smooth as possible."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance